AstraZeneca stock (GB0009895292): Q1 2026 earnings beat expectations with strong oncology growth

AstraZeneca reported Q1 2026 revenue of $13.5 billion, up 18% year-over-year, driven by oncology and rare disease segments. EPS rose to $2.15, surpassing consensus estimates, according to the company's earnings release on May 7, 2026.

AstraZeneca plc released its first-quarter 2026 financial results on May 7, 2026, showing robust growth across key therapeutic areas. Revenue increased 18% to $13.5 billion at constant exchange rates, beating analyst expectations of $13.0 billion, AstraZeneca as of 05/07/2026. Core EPS climbed 22% to $2.15, while the company reaffirmed its full-year guidance for mid- to high-single-digit revenue growth.

The strong performance was led by the oncology portfolio, which grew 25% to $6.2 billion, fueled by blockbusters like Enhertu and Imfinzi. Rare diseases and bio-pharmaceuticals segments also contributed significantly, with total growth reflecting AstraZeneca's focus on innovative medicines amid US market demand.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AstraZeneca plc
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Cambridge, UK
• Core markets: US, Europe, Emerging Markets
• Key revenue drivers: Oncology, Rare Diseases, BioPharmaceuticals
• Home exchange/listing venue: London Stock Exchange (AZN), Nasdaq (AZN)
• Trading currency: GBP (primary), USD (ADR)

AstraZeneca: core business model

AstraZeneca plc develops and commercializes prescription medicines in oncology, rare diseases, and bio-pharmaceuticals including cardiovascular, renal, metabolism, and respiratory & immunology. The company operates globally with a strong emphasis on R&D, investing over 20% of sales in innovation, as reported in its 2025 annual report published March 2026, AstraZeneca IR as of 03/2026. Its business model relies on a portfolio of differentiated products targeting high-unmet needs.

Key to its strategy is the 'Ambition 2030' framework, aiming for $80 billion in total revenue by 2030 through pipeline expansion and acquisitions. AstraZeneca's US exposure is significant, with over 40% of revenue from North America, making it relevant for US investors tracking biopharma leaders.

Main revenue and product drivers for AstraZeneca

Oncology remains the largest driver, accounting for 46% of Q1 2026 revenue. Enhertu sales surged 65% to $1.8 billion, while Imfinzi and Tagrisso contributed $2.1 billion combined, per the Q1 earnings on May 7, 2026, AstraZeneca as of 05/07/2026. Rare diseases grew 28%, led by Alexion-acquired products like Soliris.

BioPharmaceuticals added steady growth from Farxiga in cardio-renal and Symbicort in respiratory. The US market drives much of this, with oncology approvals from the FDA boosting adoption among American patients and payers.

Industry trends and competitive position

The biopharma sector faces patent cliffs but benefits from oncology breakthroughs and GLP-1 demand. AstraZeneca holds a strong position with 10 products exceeding $1 billion in 2025 sales, differentiating via antibody-drug conjugates like Enhertu, partnered with Daiichi Sankyo. IQVIA data for Q4 2025 shows AstraZeneca's US oncology market share at 8%, up from 6% prior year, IQVIA as of 01/2026.

Competitors like Pfizer and Merck challenge in immuno-oncology, but AstraZeneca's pipeline of 180+ programs positions it well for US investors seeking growth in precision medicine.

Why AstraZeneca matters for US investors

AstraZeneca's American Depositary Receipts trade on Nasdaq under AZN, providing direct access for US portfolios. With $15 billion+ annual US revenue, it offers exposure to healthcare spending, which represents 18% of US GDP. Recent FDA approvals, such as for datopotamab deruxtecan in 2026, enhance its relevance amid rising cancer incidence in the US.

Conclusion

AstraZeneca's Q1 2026 results highlight sustained momentum in oncology and rare diseases, supporting its growth trajectory. While pipeline execution and regulatory hurdles remain factors, the company's US-centric revenue and innovation focus provide a balanced profile for monitoring. Investors should track upcoming data readouts and full-year execution as detailed in recent disclosures.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.